Literature DB >> 16871284

Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features.

S A Wang, R P Hasserjian, J M Loew, E V Sechman, D Jones, S Hao, Q Liu, W Zhao, M Mehdi, N Galili, B Woda, A Raza.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16871284     DOI： 10.1038/sj.leu.2404316

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations.

Authors:  Hadrian Szpurka; Anna M Jankowska; Hideki Makishima; Juraj Bodo; Nelli Bejanyan; Eric D Hsi; Mikkael A Sekeres; Jaroslaw P Maciejewski
Journal:  Leuk Res       Date:  2010-03-23       Impact factor: 3.156

2.  Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis.

Authors:  Julien Broseus; Lourdes Florensa; Esther Zipperer; Susanne Schnittger; Luca Malcovati; Steven Richebourg; Eric Lippert; Jaroslav Cermak; Jyoti Evans; Morgane Mounier; José Maria Raya; François Bailly; Norbert Gattermann; Torsten Haferlach; Richard Garand; Kaoutar Allou; Carlos Besses; Ulrich Germing; Claudia Haferlach; Erica Travaglino; Elisa Luno; Maria Angeles Pinan; Leonor Arenillas; Maria Rozman; Maria Luz Perez Sirvent; Bernardine Favre; Julien Guy; Esther Alonso; Nuhri Ahwij; Andrés Jerez; Sylvie Hermouet; Marc Maynadié; Mario Cazzola; François Girodon
Journal:  Haematologica       Date:  2012-04-24       Impact factor: 9.941

3.  Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status.

Authors:  J M Raya; L Arenillas; A Domingo; B Bellosillo; G Gutiérrez; E Luño; M A Piñán; M Barbón; M L Pérez-Sirvent; M J Muruzábal; L Yánez; L García; A Lemes; J T Navarro; A Elosegi; M A Cortés; A Villegas; M A Durán; M Ardanaz; L Florensa
Journal:  Int J Hematol       Date:  2008-09-27       Impact factor: 2.490

4.  Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Authors:  C Walz; N C P Cross; R A Van Etten; A Reiter
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

5.  Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.

Authors:  Sa A Wang; Robert P Hasserjian; Patricia S Fox; Heesun J Rogers; Julia T Geyer; Devon Chabot-Richards; Elizabeth Weinzierl; Joseph Hatem; Jesse Jaso; Rashmi Kanagal-Shamanna; Francesco C Stingo; Keyur P Patel; Meenakshi Mehrotra; Carlos Bueso-Ramos; Ken H Young; Courtney D Dinardo; Srdan Verstovsek; Ramon V Tiu; Adam Bagg; Eric D Hsi; Daniel A Arber; Kathryn Foucar; Raja Luthra; Attilio Orazi
Journal:  Blood       Date:  2014-03-13       Impact factor: 22.113

6.  Refractory anemia with ring sideroblasts associated with marked thrombocytosis complicated by massive splenomegaly treated with lenalidomide resulting in resolution of splenomegaly but severe and prolonged pancytopenia.

Authors:  Gordon Taylor; Dominic Culligan; Mark A Vickers
Journal:  Case Rep Hematol       Date:  2013-04-07

7.  The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study.

Authors:  Margherita Perricone; Nicola Polverelli; Giovanni Martinelli; Lucia Catani; Emanuela Ottaviani; Elisa Zuffa; Eugenia Franchini; Arbana Dizdari; Dorian Forte; Elena Sabattini; Michele Cavo; Nicola Vianelli; Francesca Palandri
Journal:  Oncotarget       Date:  2017-06-06

8.  Characteristics of the four subtypes of myelodysplastic/myeloproliferative neoplasms.

Authors:  Huanling Wu; Shuquan Bian; Jingxue Chu; Xiaoyan Zhong; Hui Sun; Bingchang Zhang; Zhiming Lu
Journal:  Exp Ther Med       Date:  2013-02-26       Impact factor: 2.447

9.  Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy.

Authors:  C D DiNardo; N Daver; N Jain; N Pemmaraju; C Bueso-Ramos; C C Yin; S Pierce; E Jabbour; J E Cortes; H M Kantarjian; G Garcia-Manero; S Verstovsek
Journal:  Leukemia       Date:  2014-01-10       Impact factor: 11.528

10.  Anemia with thrombocytosis in an elderly male: a case of myelodysplastic syndrome-myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis.

Authors:  Ashutosh Kumar; Mili Jain; Rashmi Kushwaha; Uma Shankar Singh
Journal:  Hematol Transfus Cell Ther       Date:  2018-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.